NASDAQ:ENLV Enlivex Therapeutics (ENLV) Stock Price, News & Analysis $1.19 -0.06 (-4.42%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$1.13 -0.06 (-5.38%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About Enlivex Therapeutics Stock (NASDAQ:ENLV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Enlivex Therapeutics alerts:Sign Up Key Stats Today's Range$1.18▼$1.3150-Day Range$1.19▼$17.7652-Week Range$1.18▼$434.40Volume22,289 shsAverage Volume44,371 shsMarket Capitalization$1.82 millionP/E RatioN/ADividend YieldN/APrice Target$4,800.00Consensus RatingHold Company Overview Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore balance to dysregulated immune responses. The company’s approach is intended to address conditions in which excessive or uncontrolled inflammation contributes to disease progression. Enlivex’s lead product candidate is Allocetra-OTS, an off-the-shelf cell therapy made from apoptotic cells. The therapy is designed to reprogram the immune system toward a balanced state by helping regulate the activity of immune cells, including macrophages. The company has investigated Allocetra-OTS in severe sepsis and other inflammatory conditions, including COVID-19-related disease, and has pursued additional applications in immunology. The company was founded in Israel and conducts its research and clinical development activities primarily in Israel, while seeking to develop therapies for international markets. Enlivex was established by physician-scientist Dr. Dror Mevorach, who has been associated with the development of the company’s immune-modulating technology. Its programs remain subject to clinical testing and regulatory review before any potential commercialization.AI Generated. May Contain Errors. Read More Enlivex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreENLV MarketRank™: 3.641176470585 of 5 starsEnlivex Therapeutics scored higher than 73% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingEnlivex Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside PotentialEnlivex Therapeutics has a consensus price target of $4,800.00, representing about 403,261.3% upside from its current price of $1.19.Amount of Analyst CoverageEnlivex Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Enlivex Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Enlivex Therapeutics are expected to grow in the coming year, from ($18.40) to ($3.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enlivex Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enlivex Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnlivex Therapeutics has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.68% of the float of Enlivex Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnlivex Therapeutics has a short interest ratio ("days to cover") of 0.47, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enlivex Therapeutics has recently decreased by 85.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnlivex Therapeutics does not currently pay a dividend.Dividend GrowthEnlivex Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.41 News SentimentEnlivex Therapeutics has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Enlivex Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for ENLV on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows2 people have added Enlivex Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.02% of the stock of Enlivex Therapeutics is held by institutions.Read more about Enlivex Therapeutics' insider trading history. Receive ENLV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENLV Stock News HeadlinesEnlivex Therapeutics (ENLV) Expected to Release Earnings on FridayNovember 6, 2026 | americanbankingnews.comEnlivex Reports 79% Response Rate With Allocetra In Older Knee OA PatientsNovember 3, 2026 | rttnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out. | Weiss Ratings (Ad)Enlivex consensus price target increased by 1,500% to $1,305.60November 3, 2026 | msn.comEnlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment ResponseNovember 2, 2026 | globenewswire.comEnlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee OsteoarthritisOctober 28, 2026 | finance.yahoo.comEnlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to AppealOctober 27, 2026 | globenewswire.comEnlivex Therapeutics Ltd. announces 1-for-16 reverse share split effective October 27, 2026October 22, 2026 | msn.comSee More Headlines ENLV Stock Analysis - Frequently Asked Questions How have ENLV shares performed this year? Enlivex Therapeutics' stock was trading at $168.7680 at the beginning of the year. Since then, ENLV stock has decreased by 99.3% and is now trading at $1.19. How were Enlivex Therapeutics' earnings last quarter? Enlivex Therapeutics Ltd. (NASDAQ:ENLV) announced its quarterly earnings results on Friday, November, 14th. The company reported ($22.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($28.80) by $6.62. When did Enlivex Therapeutics' stock split? Shares of Enlivex Therapeutics reverse split before market open on Thursday, July 9th 2026.The 1-15 reverse split was announced on Tuesday, July 7th 2026. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 8th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Enlivex Therapeutics IPO? Enlivex Therapeutics (ENLV) raised $38 million in an initial public offering (IPO) on Wednesday, July 30th 2014. The company issued 3,200,000 shares at a price of $11.00-$13.00 per share. How do I buy shares of Enlivex Therapeutics? Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enlivex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enlivex Therapeutics investors own include CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), NVIDIA (NVDA), C3.ai (AI), Alibaba Group (BABA), Carnival (CCL) and Southwest Airlines (LUV). Company Calendar Today11/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ENLV's financial health is in the Red zone, according to TradeSmith. ENLV has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ENLV CIK1596812 Webwww.enlivex.com Phone(728) 662-3301Fax972-2620-8070Employees34Year Founded2012Price Target and Rating Average Price Target for Enlivex Therapeutics$4,800.00 High Price Target$4,800.00 Low Price Target$4,800.00 Potential Upside/Downside+403,261.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio119.39 Quick Ratio119.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1,955.31 per share Price / Book0.00Miscellaneous Outstanding Shares1,530,000Free Float1,344,000Market Cap$1.82 million OptionableOptionable Beta1.63 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:ENLV) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
